Phaseline

Companies › Guangzhou Lupeng Pharmaceutical Company

Guangzhou Lupeng Pharmaceutical Company: clinical trials, targets and expected readouts

3 active drug programs in 13 registered trials: 8 Phase 1, 4 Phase 2, 1 Phase 3; Oncology, Neurology, Other, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rocbrutinib (LP-168)
BTK inhibitor
BTKPhase 3Mantle Cell Lymphoma; Mantle Cell Lymphoma (MCL); Diffuse Large B-Cell Lymphoma (DLBCL); Relapsing-remitting Multiple Sclerosis (RRMS) …Mar 2027
Lacutoclax (LP-108)
selective BCL-2 inhibitor
BCL2Phase 2Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Acute Myeloid LeukemiaDec 2027
LP-128–Phase 1Chronic Hepatitis bDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05716087Rocbrutinib (LP-168)Phase 2Mantle Cell Lymphoma (MCL)OncologyDec 2024
NCT07374224Rocbrutinib (LP-168)Phase 1Clinical PharmacologyOtherJun 2026
NCT05130567LP-128Phase 1Chronic Hepatitis bInfectious diseaseDec 2026
NCT04993690Rocbrutinib (LP-168)Phase 1B-cell LymphomaOncologyMar 2027
NCT06251180Rocbrutinib (LP-168)Phase 1B-cell Non-Hodgkin LymphomaOncologyJun 2027
NCT07189065Rocbrutinib (LP-168)Phase 2Diffuse Large B-Cell Lymphoma (DLBCL)OncologyDec 2027
NCT07570017Rocbrutinib (LP-168)Phase 1DLBCLOncologyDec 2027
NCT05641259Lacutoclax (LP-108)Phase 1Acute Myeloid LeukemiaOncologyDec 2027
NCT07609823Lacutoclax (LP-108)Phase 2Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaOncologyMar 2028
NCT07776743Rocbrutinib (LP-168)Phase 2Relapsing-remitting Multiple Sclerosis (RRMS)NeurologyJun 2028
NCT07609862Rocbrutinib (LP-168)Phase 1Mantle Cell Lymphoma (MCL)OncologyJun 2029
NCT07609862Rocbrutinib (LP-168)Phase 1Mantle Cell Lymphoma (MCL)OncologyJun 2029
NCT07377578Rocbrutinib (LP-168)Phase 3Mantle Cell LymphomaOncologyMay 2031

Targets

BTK (1) BCL2 (1)

Companies with the same targets

BeOne Medicines Ascentage Pharma Group Sanofi Eli Lilly AbbVie AstraZeneca Zenas BioPharma (USA) Carna Biosciences Merck & Co. (MSD) Acerta Pharma

Companies built like this

NOBO Medicine TransThera Sciences (Nanjing) Shanghai Fosun Pharmaceutical Industrial Development Dizal Pharmaceuticals Nurix Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.